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Salt-inducible kinases (SIKs) regulate
TGFβ-mediated transcriptional and
apoptotic responses
Luke D. Hutchinson1,3, Nicola J. Darling1, Stephanos Nicolaou2,4, Ilaria Gori2, Daniel R. Squair1, Philip Cohen1,
Caroline S. Hill2 and Gopal P. Sapkota 1
Abstract
The signalling pathways initiated by members of the transforming growth factor-β (TGFβ) family of cytokines control
many metazoan cellular processes, including proliferation and differentiation, epithelial–mesenchymal transition (EMT)
and apoptosis. TGFβ signalling is therefore strictly regulated to ensure appropriate context-dependent physiological
responses. In an attempt to identify novel regulatory components of the TGFβ signalling pathway, we performed a
pharmacological screen by using a cell line engineered to report the endogenous transcription of the TGFβ-responsive
target gene PAI-1. The screen revealed that small molecule inhibitors of salt-inducible kinases (SIKs) attenuate
TGFβ-mediated transcription of PAI-1 without affecting receptor-mediated SMAD phosphorylation, SMAD complex
formation or nuclear translocation. We provide evidence that genetic inactivation of SIK isoforms also attenuates
TGFβ-dependent transcriptional responses. Pharmacological inhibition of SIKs by using multiple small-molecule
inhibitors potentiated apoptotic cell death induced by TGFβ stimulation. Our data therefore provide evidence for a
novel function of SIKs in modulating TGFβ-mediated transcriptional and cellular responses.
Introduction
Signalling pathways initiated by the TGFβ family of
cytokines are amongst the most prevalent and diverse in
metazoan biology, and regulate a multitude of processes,
including cellular proliferation and differentiation,
epithelial–mesenchymal transition (EMT), cell migration,
immunoregulation and apoptotic cell death in a context-
dependent manner1–6. Consequently, perturbations
within the signalling pathway have been associated with
the pathogenesis of many human disorders including
cancer. For example, in normal epithelial cells, TGFβ has
a tumour-suppressive function, principally through its
ability to induce cytostasis and apoptotic cell death7–9. In
contrast, during tumour progression, the suppressive
effect of TGFβ is lost, and in certain cancers, corruption
of the signalling pathway can result in TGFβ exerting a
pro-oncogenic effect7,10,11. Inhibition of the TGFβ path-
way has therefore been proposed as a potential ther-
apeutic strategy in certain pathological contexts12,13.
However, the highly pleiotropic and context-dependent
nature of TGFβ signalling has provided a considerable
challenge for pharmacological intervention14. Elucidating
the context-dependent regulatory mechanisms underlying
TGFβ signalling is therefore of considerable importance
in identifying novel therapeutic interventions.
TGFβ signalling is initiated upon the binding of TGFβ
ligand dimers to cognate transmembrane receptor
serine–threonine protein kinases to form activated het-
erotetrameric receptor complexes containing two type I
and two type II receptors15. This allows the constitutively
active type II receptor to phosphorylate multiple serine
and threonine residues within the cytoplasmic domain of
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the type I receptor, which enables the type I receptor to
bind and phosphorylate the SMAD transcription factors
2/3 (SMADs2/3) at the Ser–Xxx–Ser motif at the
carboxy-terminal tail16–18. Receptor-mediated phosphor-
ylation of R-SMADs facilitates interaction with the co-
SMAD, SMAD4, followed by accumulation in the
nucleus, where the SMAD complex co-operates with
different transcriptional co-regulators to modulate the
expression of hundreds of target genes in a cell-type- and
context-dependent manner18–20.
Previously, we developed an endogenous transcriptional
reporter cell line for the TGFβ pathway using
CRISPR–Cas9 genome editing technology21 by inserting
ﬁreﬂy (Photinus pyralis) luciferase and green ﬂuorescent
protein (GFP) at the native TGFβ-responsive target gene
plasminogen activator inhibitor 1 (PAI-1) locus (Fig. 1a).
The transcription of PAI-1 is induced in response to
TGFβ signals in different cell types in a SMAD-dependent
manner22,23. Moreover, the promoter region of the
endogenous PAI-1 gene has been frequently utilised in
order to generate conventional luciferase-based over-
expression reporter systems for the study of
TGFβ-mediated transcriptional regulation24. In order to
identify novel regulatory components of the TGFβ path-
way, we performed a pharmacological screen in this
endogenous TGFβ-responsive transcriptional reporter
cell line using a panel of small molecules obtained from
the MRC International Centre for Kinase Proﬁling at the
University of Dundee. The panel consisted predominantly
of selective and potent inhibitors of protein kinases, but
also included a small number of compounds that target
components of the ubiquitin–proteasome system (UPS).
The screen identiﬁed salt-inducible kinases (SIKs), which
are members of the AMP-activated protein kinase
(AMPK)-related subfamily of serine–threonine speciﬁc
kinases25,26, as potential novel regulators of
TGFβ-mediated gene transcription. In this study, we have
therefore investigated the role of SIKs in regulating the
TGFβ signalling pathway.
Results
Identiﬁcation of salt-inducible kinases as novel regulators
of TGFβ-mediated gene transcription
We tested the utility of the endogenous
TGFβ-responsive transcriptional reporter U2OS cell line
(U2OS 2G) (Fig. 1a) for a pharmacological screen. Sti-
mulation of wild-type (WT) U2OS and U2OS 2G cells
with TGFβ1 over 24 h resulted in time-dependent induc-
tion of PAI-1 and GFP expression, respectively (Fig. 1b),
and comparable levels of SMAD3 C-terminal phosphor-
ylation in both cell lines. TGFβ induced a signiﬁcant
increase in relative luciferase activity in U2OS 2G cells
over unstimulated cells, which was blocked with SB-
505124, a selective inhibitor of the TGFβ type I receptor
(TGFβR1) kinases27,28 (Fig. 1c). Similarly, TGFβ-induced
GFP expression in U2OS 2G cells is blocked with SB-
505124 (Fig. 1d). These data conﬁrmed the suitability of
U2OS 2G cells for pharmacological screens. A 96-well
plate format pharmacological screen was performed to
identify potential novel regulators of the TGFβ pathway
(Fig. 1e). TGFβR1 inhibitors SB-505124 (refs. 27,28) and A
83-01 (ref. 29) served as positive controls, while DMSO
served as a negative control. All compounds were used at
a ﬁnal concentration of 1 µM. Both SB-505124 and A 83-
01 signiﬁcantly inhibited TGFβ-induced luciferase activity
compared with DMSO controls (Fig. 1f, g). In addition,
D4476 and LDN193189, also signiﬁcantly inhibited
TGFβ-induced luciferase activity. D4476 was initially
identiﬁed as an inhibitor of TGFβR1 (ref. 30), although
subsequent in vitro proﬁling revealed that it inhibited
casein kinase 1 (CK1) with greater potency31. LDN193189
is an ATP-competitive inhibitor of the BMP type I
receptor kinases32. However, at 1 µM concentration it also
inhibits the TGFβR1 (ref. 28). The majority of the com-
pounds used in the screen did not signiﬁcantly affect
TGFβ-induced luciferase reporter activity. Interestingly,
however, we observed that HG-9-91-01, a potent ATP-
competitive inhibitor of salt-inducible kinase (SIK) iso-
forms33, signiﬁcantly attenuated TGFβ-induced luciferase
activity (Fig. 1f, g), suggesting a possible role for SIKs in
TGFβ-induced transcription.
Characterisation of SIK inhibitors in the context of TGFβ
signalling
To explore the role of SIKs in TGFβ signalling further, in
addition to HG-9-91-01, we utilised MRT199665, a struc-
turally distinct inhibitor of SIK isoforms33 (Fig. 2a).
MRT199665 also suppressed TGFβ-induced luciferase
activity in U2OS 2G cells, as potently as SB-505124 and HG-
9-91-01 (Fig. 2b). Both HG-9-91-01 and MRT199665
inhibited the phosphorylation of a known SIK substrate
CRTC3 at S370 (refs. 33–35) compared with DMSO control
(Fig. 2c). Because kinase inhibitors often display off-target
inhibition, we tested whether the attenuation of
TGFβ-induced luciferase activity by HG-9-91-01 and
MRT199665 occurred as a result of the off-target inhibition
of the TGFβR1 upstream of SMAD2/SMAD3 phosphor-
ylation. HG-9-91-01 substantially inhibited TGFβ-induced
SMAD3 phosphorylation, to a similar extent as SB-505124,
compared with DMSO controls, whereas MRT199665 did
not (Fig. 2d), suggesting that HG-9-91-01 could inhibit
either type I or type II TGFβ receptors. Indeed, at con-
centrations of 0.1, 1 and 10 µM in vitro, HG-9-91-01
inhibited TGFβR1 (ALK5) kinase activity, whereas
MRT199665 did not (Fig. 2e). Because of this off-target
inhibition of TGFβR1 by HG-9-91-01, we decided to
employ MRT199665 as the SIK inhibitor for subsequent
experiments.
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MRT199665 attenuates the expression of endogenous
TGFβ target genes
Any compound that inhibits luciferase enzymatic
activity could potentially yield a false-positive result in
U2OS 2G cells. Therefore, to exclude this possibility for
MRT199665, we tested whether the TGFβ-induced GFP
expression in U2OS 2G cells was affected by MRT199665.
The TGFβ-induced expression of GFP in U2OS 2G cells
was inhibited with MRT199665, to the same extent as SB-
505124, compared with DMSO control (Fig. 3a), while the
TGFβ-induced SMAD2/SMAD3 C-terminal phosphor-
ylation was unaffected by MRT199665 (Fig. 3a). More-
over, MRT199665 signiﬁcantly attenuated TGFβ-induced
PAI-1 mRNA expression in WT U2OS cells (Fig. 3b). In
WT A-172 human glioblastoma cells, MRT199665 also
inhibited TGFβ-induced expression of PAI-1 mRNA, as
well as SMAD7 and connective tissue growth factor
(CTGF) mRNAs (Fig. 3c). These data demonstrate that
MRT199665 inhibits TGFβ-induced transcription of
endogenous target genes in different cells without
affecting SMAD2/SMAD3 phosphorylation.
Genetic inactivation of SIK2/3 attenuates the
TGFβ-mediated induction of PAI-1 expression
We employed genetic approaches to test the impact of
SIK kinase activity on TGFβ signalling. SIKs are members
of the AMP-activated protein kinase (AMPK)-related
subfamily of serine–threonine protein kinases that require
LKB1-mediated phosphorylation of a conserved threonine
residue within the activation loop in order to become
catalytically active25,26 (Fig. 4a). In LKB1-deﬁcient WT
HeLa cells36–38, TGFβ1 induced a 1.5-fold increase in PAI-
1 mRNA expression relative to unstimulated controls.
However, stable overexpression of catalytically active
LKB1 (LKB1WT), but not the catalytically inactive mutant
(LKB1D194A), in WT HeLa cells, signiﬁcantly enhanced
the TGFβ-induced transcription of PAI-1mRNA (Fig. 4b),
as well as PAI-1 protein levels (Fig. 4c), although the levels
of LKB1WT restored in HeLa cells were substantially
higher than the LKB1D194A mutant (Fig. 4c).
The catalytic activity of SIK isoforms can be ablated via
mutation of the activation loop threonine to alanine39,
which abolishes LKB1-mediated phosphorylation. Indeed,
in mouse embryonic ﬁbroblasts (MEFs) derived from
embryos harbouring homozygous SIK2T175A and
SIK3T163A genotypes39, the phosphorylation of CRTC3 at
S370 is substantially reduced compared with WT control
MEFs (Fig. 4d). A time-course treatment of WT MEFs
with TGFβ1 resulted in robust SMAD3 phosphorylation,
and an increase in PAI-1 protein levels at 6 h (Fig. 4e).
When homozygous SIK2T175A/SIK3T163A MEFs were
subjected to TGFβ stimulation for 6 h, the induction of
PAI-1 protein expression was substantially attenuated,
compared with WT MEFs, despite the observation of
higher SMAD3 phosphorylation in the SIK2T175A/
SIK3T163A mutant MEFs (Fig. 4f). Consistent with this, the
relative PAI-1 mRNA expression in response to TGFβ
stimulation was signiﬁcantly reduced in MEFs derived
from two independent homozygous SIK2T175A/SIK3T163A
mice relative to WT MEFs (Fig. 4g).
Impact of SIK isoforms on TGFβ-dependent proliferative
responses
TGFβ inhibits epithelial cell proliferation, in part through
transcriptional upregulation of cyclin-dependent kinase
(CDK) inhibitors p21CIP1 and p27KIP1, and downregulation
of the proto-oncogene c-Myc1,4,7. In HaCaT cells, we
observed an increase in endogenous p27KIP1 and p21CIP1
protein levels, and a decrease in c-Myc protein levels over a
24-h time course of TGFβ treatment (Fig. 5a). Rather sur-
prisingly, treatment of HaCaT cells with MRT199665
resulted in increased expression of both p21CIP1 and
p27KIP1, even in the absence of TGFβ treatment, and this
increase was more pronounced after stimulation of cells
with TGFβ compared with DMSO controls (Fig. 5b). This
suggested that inhibition of SIKs alone may exert cytostatic
effects. When we analysed the proliferation of HaCaT cells
over a period of 170 h, the control cells displayed a typical
sigmoid growth curve, while TGFβ treatment caused a
signiﬁcant inhibition of proliferation after 100 h (Fig. 5c).
Under these conditions, MRT199665 profoundly sup-
pressed cell proliferation at all time points, regardless of
TGFβ treatment (Fig. 5c). In line with this, when we ana-
lysed MEFs from Fig. 4f for p27KIP1 levels, we also observed
a substantial increase in p27KIP1 levels in MEFs derived
from homozygous SIK2T175A/SIK3T163A KI mice relative to
(see ﬁgure on previous page)
Fig. 1 Pharmacological screen in endogenous TGFβ transcriptional reporter cells. a Schematic representation of the dual-reporter cassette
inserted in-frame with the ATG start codon of the endogenous PAI-1 gene in U2OS human osteosarcoma cells. b Immunoblot analysis of wild-type
U2OS and U2OS 2G transcriptional reporter cell lines stimulated with TGFβ1 (5 ngmL
−1) for the indicated durations. Cell lysates were resolved via
SDS-PAGE, and membranes were subjected to immunoblotting with the indicated antibodies. c Luciferase assay analysis of U2OS 2G transcriptional
reporter cells incubated with either SB-505124 or DMSO control in the presence of TGFβ1 stimulation. d Immunoblot analysis of U2OS transcriptional
reporter cells incubated with either SB-505124 or DMSO control in the presence of TGFβ1 stimulation. Cell lysates were resolved via SDS-PAGE, and
membranes were subjected to immunoblotting with the indicated antibodies. e Schematic representation of the experimental workﬂow for the
pharmacological screen in U2OS 2G transcriptional reporter cells. f, g The top ﬁve hits obtained from three independent experiments that reduced
TGFβ-induced luciferase activity. Data indicate the mean luciferase activity values (±SEM) relative to internal DMSO controls.
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WT mice, irrespective of TGFβ stimulation (Fig. 5d), sug-
gesting that SIK kinase activity plays a fundamental role in
suppressing p27KIP1 protein levels. To further conﬁrm that
SIK inhibition promotes cytostasis independent of TGFβ
stimulation, we exploited SMAD3–/– HaCaT cells, and
showed that treatment of both WT and SMAD3–/–
HaCaT cells with MRT199665 resulted in an increase in
p21CIP1 and p27KIP1 levels compared with untreated control
cells (Fig. 5e).
In many epithelial cells, TGFβ-induced cytostasis,
through the induction of p21CIP1 and p27KIP1, and sup-
pression of c-Myc, is often necessary for subsequent
TGFβ-dependent cell fates, such as differentiation, EMT
and apoptosis. Our unexpected ﬁndings that inhibition of
Fig. 2 Characterisation of pharmacological SIK inhibitors in the context of TGFβ signaling. a The chemical structures of HG-9-91-01 and
MRT199665, ATP-competitive small-molecule inhibitors of SIK isoforms. b Luciferase assay analysis of U2OS 2G transcriptional reporter cells incubated
with DMSO, SB-505124, HG-9-91-01 or MRT199665, in the presence or absence of TGFβ1 stimulation. c Immunoblot analysis of endogenous CRTC3
phosphorylation in wild-type U2OS cells following incubation with DMSO, MRT199665 or HG-9-91-01. Cell lysates were subjected to endogenous
CRTC3 immunoprecipitation (IP) and subsequently resolved via SDS-PAGE. Membranes were subjected to immunoblotting with the indicated
antibodies. d Immunoblot analysis of wild-type U2OS cells incubated with SB-505124, HG-9-91-01 or MRT199665 in the presence of TGFβ1
stimulation. Cell lysates were resolved via SDS-PAGE, and membranes were subjected to immunoblotting with the indicated antibodies. e In vitro
kinase assay analysis of recombinant constitutively active TGFβR1 (ALK5) in the presence of HG-9-91-01 or MRT199665 at the three indicated
concentrations. Values denote the mean percentage activity remaining (±SD).
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SIK isoforms induces the expression of p21CIP1 and
p27KIP1 levels, independent of TGFβ, prompted us to
explore whether TGFβ-induced epithelial cell fates are
sensitised by SIK inhibitors. We therefore sought to
investigate whether inhibition of SIK isoforms sensitises
cells to TGFβ-induced EMT and apoptosis.
Pharmacological inhibition of SIKs potentiates
TGFβ-mediated apoptosis
NMuMG murine mammary epithelial cells undergo
both EMT and apoptosis upon TGFβ stimulation40–44.
When we tested the effect of MRT199665 on
TGFβ-induced EMT in NMuMG cells, which usually
takes around 24–48 h, it became apparent that there was
profound cell death within 12–24 h, prompting us to
investigate apoptosis. The apoptotic response to TGFβ is
mediated in part by the executioner cysteine–aspartic acid
protease, caspase-3. Caspase-3 is synthesised as an inac-
tive proenzyme, and requires proteolytic cleavage in order
to become catalytically active. Apoptosis can thus be
monitored via the detection of the cleaved, and hence
activated, form of caspase-3. Furthermore, activated
caspase-3 mediates the proteolytic cleavage of poly-
(ADP-ribose) polymerase (PARP), which can also be used
to monitor apoptosis. Stimulation of NMuMG cells with
TGFβ1 over a period of 72 h induced the activation of
caspase-3 and subsequent cleavage of PARP, with max-
imal cleavage observed at 24 h (Fig. 6a). The expression of
the pro-apoptotic factor Bim was observed at 48–72 h
(Fig. 6a). In these cells, SIK inhibitors HG-9-91-01 and
MRT199665 resulted in reduction of phospho-CRTC3-
S370 (Fig. 6b). The TGFβ-induced cleavage of caspase-3
and PARP at 24 h was blocked by SB-505124 (Fig. 6c).
Interestingly, in cells incubated with MRT199665 and
TGFβ1, the appearance of cleaved caspase-3 and PARP
was substantially enhanced, compared with TGFβ-treated
DMSO controls (Fig. 6c). Under these conditions, the
expression of pro-apoptotic factors BIM, BAD, BAK and
BIK did not increase when cells were treated with
MRT199665 and TGFβ1 compared with TGFβ-treated
Fig. 3 MRT199665 attenuates TGFβ-mediated transcription in human cancer cell lines. a Immunoblot analysis of U2OS 2G transcriptional
reporter cells incubated with either SB-505124 or MRT199665 in the presence of TGFβ1 stimulation. Cell lysates were resolved via SDS-PAGE, and
membranes were subjected to immunoblotting with the indicated antibodies. b RT-qPCR analysis of PAI-1 mRNA expression in wild-type U2OS
human osteosarcoma cells incubated with either SB-505124 or MRT199665 in the presence or absence of TGFβ1 stimulation. c RT-qPCR analysis of
PAI-1, SMAD7 and CTGF mRNA expression in wild-type A-172 human glioblastoma cells incubated with either SB-505124 or MRT199665 in the
presence or absence of TGFβ1 stimulation.
Hutchinson et al. Cell Death and Disease           (2020) 11:49 Page 6 of 17
Ofﬁcial journal of the Cell Death Differentiation Association
DMSO controls (Fig. 6c). However, in cells treated with
MRT199665 and TGFβ1, the levels of apoptosis sup-
pressor protein MCL-1 were substantially attenuated,
compared with TGFβ-treated DMSO controls (Fig. 6c). In
the absence of TGFβ1, MRT199665 alone did not induce
the cleavage of caspase-3 and PARP (Fig. 6d). Further-
more, MRT199665+TGFβ1 treatment resulted in the
maximal and more pronounced appearance of cleaved
caspase-3 and PARP much earlier (12 h) than TGFβ1-
alone treatment (Fig. 6d). When we monitored apoptosis
using Annexin V and DAPI staining, treatment of
NMuMG cells with TGFβ for 24 h resulted in a sub-
stantial increase in Annexin V-positive apoptotic cells
over controls, while this was reversed by SB-505124.
Treatment of cells with MRT199665 signiﬁcantly
enhanced TGFβ-induced apoptosis (Fig. 6e). Similarly,
when we analysed cell viability, TGFβ1 treatment resulted
in a decrease in the number of viable cells compared with
DMSO controls, while this was reversed by SB-505124
(Fig. 6f). In contrast, treatment of cells with MRT199665
resulted in almost complete loss of viable cells (Fig. 6f).
Collectively, these results indicate that inhibition of SIK
isoforms by MRT199665 can potentiate TGFβ-mediated
apoptotic cell death in NMuMG cells.
Previous reports have revealed that the clinically
approved tyrosine kinase inhibitors (TKIs) bosutinib and
dasatinib are also capable of inhibiting SIK isoforms, with
in vitro IC50 values in the low nanomolar range
45,46
(Fig. 7a). Both bosutinib and dasatinib inhibit the kinase
activity of the BCR-Abl fusion, as well as Src and BTK
(Fig. 7b), and are used to treat Philadelphia chromosome-
positive (Ph+) chronic myelogenous leukaemia (CML)
and acute lymphoblastic leukaemia (ALL)47,48. In WT
U2OS cells, both compounds reduced the phospho-
CRTC3 (S370) levels compared with DMSO controls,
suggesting effective SIK inhibition (Fig. 7c). Like
Fig. 4 Genetic evidence for the involvement of SIK isoforms in TGFβ-mediated PAI-1 expression. a Sequence alignment of the activation
segment of the human AMPKα catalytic subunits and the 13 members of the AMPK-related family of protein kinases. The asterisk indicates the
conserved activation (T) loop, threonine residue, which is phosphorylated by LKB1. b RT-qPCR analysis of PAI-1 mRNA expression in wild-type HeLa
cervical adenocarcinoma cells and HeLa cells overexpressing either LKB1WT or LKB1D194A following TGFβ1 stimulation. c Immunoblot analysis of wild-
type HeLa cells and HeLa cells overexpressing either LKB1WT or LKB1D194A following TGFβ1 stimulation. Cell lysates were resolved via SDS-PAGE, and
membranes were subjected to immunoblotting with the indicated antibodies. d Immunoblot analysis of endogenous CRTC3 phosphorylation in
wild-type MEFs and MEFs derived from homozygous SIK2T175A/SIK3T163A knockin (KI) mouse embryos. Cell lysates were subjected to endogenous
CRTC3 IP and subsequently resolved via SDS-PAGE. Membranes were subjected to immunoblotting with the indicated antibodies. e Immunoblot
analysis of wild-type MEFs stimulated with TGFβ1 for the indicated durations. Cell lysates were resolved via SDS-PAGE, and membranes were
subjected to immunoblotting with the indicated antibodies. f Immunoblot analysis of wild-type and homozygous SIK2T175A/SIK3T163A MEFs. Cell
lysates were resolved via SDS-PAGE, and membranes were subjected to immunoblotting with the indicated antibodies. g RT-qPCR analysis of PAI-1
mRNA expression in wild-type and homozygous SIK2T175A/SIK3T163A KI MEFs following TGFβ1 stimulation.
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MRT199665, neither bosutinib nor dasatinib inhibited the
TGFβ-induced phosphorylation of SMAD2/SMAD3, but
both inhibited the TGFβ-induced expression of GFP in
U2OS 2G cells (Fig. 7d), and endogenous PAI-1 in WT
U2OS cells (Fig. 7e). As in U2OS cells, in NMuMG cells,
neither compound affected the TGFβ-induced phos-
phorylation of SMAD2/3 relative to controls (Fig. 7f).
Excitingly, treatment of NMuMG cells with bosutinib for
24 h substantially enhanced the TGFβ-induced levels of
cleaved caspase-3 and PARP to a similar extent as
MRT199665 (Fig. 7g), suggesting that the increased
TGFβ-induced apoptosis caused by bosutinib is likely due
to its ability to inhibit SIK isoforms.
SIKs do not appear to affect SMAD2/3 phosphorylation
and their nuclear translocation directly
We sought to investigate the molecular mechanisms by
which SIK2/SIK3 might regulate TGFβ signalling. To
explore whether SIKs exert effects on TGFβ signalling
through direct phosphorylation of SMAD proteins, in vitro
kinase assays were performed. GST-SIK2 and GST-SIK3,
but not MBP-SIK1, phosphorylated SMAD2, SMAD3 and
SMAD4 in vitro (Fig. S1), while SIK inhibitor HG-9-91-01
blocked SMAD3 phosphorylation (Fig. S2A). Mass spec-
trometry identiﬁed Thr247 as the predominant SIK2/3
phosphorylated residue on SMAD3. This residue is con-
served in SMAD2, SMAD3, SMAD4 and SMAD9 proteins
(Fig. 8a). The TGFβ-induced transcription of PAI-1 has
been previously reported to be speciﬁc to SMAD3
(refs. 23,49). Consistent with this, treatment of wild-type and
SMAD3–/– HaCaT cells with human TGFβ1 resulted in C-
terminal phosphorylation of SMAD2; however, PAI-1
expression was completely abrogated in SMAD3–/– cells
but not in WT cells (Figs. 8b and S2B). Transient restora-
tion of SMAD3 expression with FLAG-SMAD3WT was
sufﬁcient to partially restore TGFβ-induced PAI-1 expres-
sion (Fig. 8b). However, restoration of the SIK-phospho-
deﬁcient mutant FLAG-SMAD3T247A in SMAD3–/– cells
also restored TGFβ-induced PAI-1 expression, to similar
levels observed with SMAD3WT (Fig. 8b), suggesting that
Fig. 5 SIK inhibition enhances TGFβ-independent cytostasis. a Immunoblot analysis of wild-type HaCaT cells stimulated with TGFβ1 for the
indicated durations. Cell lysates were resolved via SDS-PAGE, and membranes were subjected to immunoblotting with the indicated antibodies.
b Immunoblot analysis of wild-type HaCaT cells incubated with DMSO, SB-505124 or MRT199665, in the presence or absence of TGFβ1 stimulation.
Cell lysates were resolved via SDS-PAGE, and membranes were subjected to immunoblotting with the indicated antibodies. c The proliferation of
HaCaT cells incubated with either DMSO or MRT199665, in the presence or absence of TGFβ1, was monitored by using an IncuCyte ZOOM Live-Cell
Analysis System. Cells were imaged every 2 h over a period of 170 h, and the percent conﬂuence was determined using IncuCyte ZOOM Analysis
Software (Sartorius). d Immunoblot analysis of p27KIP1 in wild-type and homozygous SIK2T175A/SIK3T163A MEFs following TGFβ1 stimulation from the
experiment presented in Fig. 4f. The other control immunoblots are thus identical to Fig. 4f. e Immunoblot analysis of wild-type and SMAD3–/–
HaCaT cells incubated in the presence or absence of MRT199665. Cell lysates were resolved via SDS-PAGE, and membranes were subjected to
immunoblotting with the indicated antibodies.
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phosphorylation of SMAD3 at Thr247 by SIKs is unlikely to
explain the effects of SIKs in TGFβ signalling.
Next, we tested whether SIK2/SIK3 inhibition disrupts
the formation of SMAD2/SMAD3–SMAD4 complexes,
or nuclear accumulation of SMADs. In U2OS cells stably
overexpressing GFP-SMAD4, neither the basal nor
TGFβ-induced increase in co-precipitation of SMAD2/3
in GFP-SMAD4 IPs was affected by treatment of cells
with MRT199665 (Fig. 8c). TGFβ induced a robust
nuclear accumulation of phosphorylated SMAD2 and
SMAD3 levels in nuclear fractions over unstimulated
conditions, or when cells were treated with SB-505124
(Fig. 8d). MRT199665 treatment did not affect the
cytoplasmic/nuclear distribution of phosphorylated
SMAD2/SMAD3 relative to controls in both unstimu-
lated and TGFβ1-stimulated conditions (Fig. 8d).
Consistent with this, in cells stably overexpressing GFP-
SMAD2, MRT199665 did not prevent the nuclear
translocation of GFP-SMAD2 following TGFβ1 stimu-
lation when analysed via immunoﬂuorescence (IF)
(Fig. 8e). As inhibition of SIK isoforms with MRT199665
does not appear to impact the formation of the SMAD2/
3–SMAD4 complex or the nuclear accumulation of
phosphorylated SMAD2/3, the effect of MRT199665 is
likely to occur further downstream.
Discussion
In this study, we identiﬁed inhibitors of SIK isoforms as
novel candidates for the inhibition of TGFβ-induced
transcription. We established that inhibiting SIK protein
kinase activity, both pharmacologically and genetically,
attenuates the TGFβ-induced expression of endogenous
Fig. 6 MRT199665 potentiates TGFβ-mediated apoptotic cell death. a Immunoblot analysis of wild-type NMuMG murine mammary epithelial
cells stimulated with TGFβ1 for the indicated durations. Cell lysates were resolved via SDS-PAGE, and membranes were subjected to immunoblotting
with the indicated antibodies. b Immunoblot analysis of endogenous CRTC3 phosphorylation in wild-type NMuMG cells following incubation with
DMSO, MRT199665 or HG-9-91-01. Cell lysates were subjected to CRTC3 IP and subsequently resolved via SDS-PAGE. Membranes were subjected to
immunoblotting with the indicated antibodies. c Immunoblot analysis of wild-type NMuMG cells incubated with either SB-505124 (SB) or MRT199665
(MRT) in the presence of TGFβ1 stimulation. Cell lysates were resolved via SDS-PAGE, and membranes were subjected to immunoblotting with the
indicated antibodies. d Immunoblot analysis of wild-type NMuMG cells incubated with MRT199665 in the presence or absence of TGFβ1 stimulation
for the indicated durations. Cell lysates were resolved via SDS-PAGE, and membranes were subjected to immunoblotting with the indicated
antibodies. e Annexin V staining analysis of wild-type NMuMG cells incubated with DMSO, SB-505124 or MRT199665 in the presence of TGFβ1
stimulation. Data represent the percentage of cells positive for annexin V staining from three independent experiments (5 × 104 cell counts per
sample per replicate). f Crystal violet cellular viability analysis of wild-type NMuMG cells incubated with DMSO, SB-505124 or MRT199665 in the
presence of TGFβ1 stimulation. Data represent cellular viability relative to unstimulated DMSO control cells.
Hutchinson et al. Cell Death and Disease           (2020) 11:49 Page 9 of 17
Ofﬁcial journal of the Cell Death Differentiation Association
PAI-1 transcript and protein in different cells. Moreover,
the attenuation of TGFβ-induced PAI-1 by MRT199665
occurred without affecting phosphorylation of SMAD
proteins, the SMAD2/SMAD3–SMAD4 interaction or the
nuclear accumulation of activated SMADs. We propose
that SIK isoforms function at the level of transcriptional
regulation in the context of TGFβ signalling.
In every cell line we tested, TGFβ-induced endogenous
PAI-1 transcript and protein levels were reduced by both
pharmacological and genetic ablation of SIK kinase activity.
PAI-1 is a serine protease inhibitor (Serpin) that functions
as the physiological inhibitor of the serine proteases tissue-
type plasminogen activator (t-PA) and urokinase-type
plasminogen activator (u-PA), and controls ﬁbrinolysis.
Increased plasma levels of PAI-1 have been associated with
a number of diseases, including thrombotic vascular dis-
orders50. As inhibition of SIK isoforms attenuates
TGFβ-induced expression of PAI-1, pharmacological SIK
inhibitors may have novel therapeutic potential if they
demonstrably suppress excessive PAI-1 levels in vivo.
SIK1 was previously linked to the regulation of TGFβ
signalling51,52, in which it was shown that SIK1 was a
direct transcriptional target of TGFβ signalling, and
played a role in the degradation of ALK5 through SIK1/
SMAD7/SMURF2 complex. During the course of our
experiments, we did not observe any change in protein
Fig. 7 The clinically approved tyrosine kinase inhibitors (TKIs) bosutinib and dasatinib impact TGFβ-mediated transcriptional and cellular
responses. a The chemical structures of the clinically approved small-molecule tyrosine kinase inhibitors (TKIs) bosutinib and dasatinib. b In vitro
nanomolar IC50 values of bosutinib and dasatinib against the protein kinases Abl, BTK, Src and the three SIK isoforms (adapted from Ozanne et al.
45).
c Immunoblot analysis of endogenous CRTC3 phosphorylation in wild-type U2OS cells following incubation with DMSO, MRT199665, bosutinib or
dasatinib. Cell lysates were subjected to CRTC3 IP and subsequently resolved via SDS-PAGE. Membranes were subjected to immunoblotting with the
indicated antibodies. d Immunoblot analysis of U2OS 2G transcriptional reporter cells incubated with SB-505124, bosutinib or dasatinib in the
presence of TGFβ1 stimulation. Cell lysates were resolved via SDS-PAGE, and membranes were subjected to immunoblotting with the indicated
antibodies. e Immunoblot analysis of wild- type U2OS cells incubated with SB-505124, bosutinib or dasatinib in the presence of TGFβ1 stimulation.
Cell lysates were resolved via SDS-PAGE, and membranes were subjected to immunoblotting with the indicated antibodies. f Immunoblot analysis of
wild-type NMuMG cells incubated with SB-505124, MRT199665, bosutinib or dasatinib in the presence of TGFβ1 stimulation. Cell lysates were resolved
via SDS-PAGE, and membranes were subjected to immunoblotting with the indicated antibodies. g Immunoblot analysis of wild-type NMuMG cells
incubated with SB-505124, MRT199665 or bosutinib in the presence of TGFβ1 stimulation. Cell lysates were resolved via SDS-PAGE, and membranes
were subjected to immunoblotting with the indicated antibodies.
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expression of either SIK2 or SIK3 upon TGFβ signal-
ling, suggesting that unlike SIK1, these two isoforms
are not transcriptional targets of TGFβ signalling. Our
data indicate that the inhibition of the kinase activity of
SIK2 and SIK3 is sufﬁcient to suppress the
TGFβ-induced upregulation of PAI-1, whereas RNAi-
mediated depletion of SIK1 has been reported to
enhance PAI-1 mRNA expression in response to TGFβ
stimulation51. It is therefore apparent that the exact
roles of the different SIK isoforms in regulating TGFβ
signalling remain to be elucidated and are most likely
context dependent.
Fig. 8 SIK2 and SIK3 isoforms phosphorylate SMAD3 in vitro; however, MRT199665 does not affect SMAD interaction or nuclear
translocation. a Sequence alignment of the eight human SMAD proteins. The asterisk indicates the amino acid residue in recombinant SMAD3
(Thr247) that was identiﬁed via phosphorylation-site mapping analysis. b Immunoblot analysis of wild-type HaCaT cells and SMAD3–/– cells
following transient overexpression of either FLAG-SMAD3WT or FLAG-SMAD3T247A mutant, in the presence or absence of TGFβ1 stimulation. Cell
lysates were resolved via SDS-PAGE, and membranes were subjected to immunoblotting with the indicated antibodies. c U2OS cells stably
expressing GFP-SMAD4 were incubated with DMSO, SB-505124 or MRT199665 in the presence or absence of TGFβ1 stimulation. Cell lysates were
subjected to GFP immunoprecipitation and resolved via SDS-PAGE. Membranes were subjected to immunoblotting with the indicated antibodies.
d Immunoblot analysis of SMAD2 and SMAD3 localisation in wild-type U2OS cells following incubation with DMSO, SB-505124 or MRT199665, in
the presence or absence of TGFβ1 stimulation. Cell lysates were separated into cytoplasmic (C) and nuclear (N) fractions, resolved via SDS-PAGE
and membranes were subjected to immunoblotting with the indicated antibodies. e Immunoﬂuorescence analysis of U2OS cells stably expressing
GFP-SMAD2 following incubation with DMSO, SB-505124 (SB) or MRT199665 (MRT) in the presence or absence of TGFβ1 stimulation (images are
representative). Scale bar indicates 10 µm.
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The precise mechanisms by which SIK isoforms reg-
ulate the TGFβ-induced expression of PAI-1 or other
genes remain to be resolved. As serine–threonine protein
kinases, SIK isoforms act by phosphorylating protein
substrates. In the case of TGFβ signalling, these could be
components of the SMAD-transcriptional complexes or
key transcriptional modulators, enhancers, suppressors
and/or adaptors that modulate the function of these
transcriptional cofactors in order to control the tran-
scriptional activity of SMAD2/SMAD3. Unless the core
SMAD2/3 transcriptional complexes are found to be
substrates of SIKs, the impact of SIKs in TGFβ target gene
transcription is likely to be determined by whether the
individual target gene promoters recruit speciﬁc SIK
substrates. It is known that SMAD2/SMAD3 do not
directly regulate target gene transcription, but instead
facilitate the recruitment of various transcriptional co-
activators/co-repressors or histone-modifying enzymes20.
SIKs have been reported to regulate the Toll-like receptor
(TLR) signalling through their ability to phosphorylate the
transcriptional coactivator CRTC3 and so reduce CREB-
dependent transcription of the IL10 gene33. It is therefore
conceivable that SIKs may employ similar mechanisms to
regulate SMAD-associated transcriptional cofactors to
modulate the transcription of speciﬁc subsets of
TGFβ-target genes. A phospho-proteomic approach using
both SIK inhibitors and SIK2T175A/SIK3T163A MEFs might
uncover potential SIK substrates that underpin the reg-
ulation of TGFβ-induced transcription of distinct genes.
In many epithelial cell types, TGFβ-induced cytostasis,
through p15INK4B, p21CIP1 and p27KIP1 (refs. 1,4), is often
followed by context-dependent cell fates, such as differ-
entiation, EMT or apoptosis53,54. Interestingly, inhibition
of SIKs induced p21CIP1 and p27KIP1 expression inde-
pendently of TGFβ stimulation. Perhaps due in part to
this, SIK inhibitors sensitise NMuMG cells for
TGFβ-induced apoptosis. These observations imply that
SIK inhibitors could be employed to sensitise cancer cells
for apoptosis in those cells that TGFβ induces apoptosis.
This could be easily tested by using clinically approved
anticancer drugs dasatinib and bosutinib that inhibit SIK
isoforms in addition to their intended targets in a number
of cancer cell types, including multiple Burkitt’s lym-
phoma (BL) cell lines42,55–57, hepatocellular carcinoma58
and prostate carcinoma cells59–61 that have been reported
to undergo apoptosis in response to TGFβ.
Our ﬁndings place SIK isoforms as modulators of a
subset of TGFβ-induced transcriptional and physiological
responses. Understanding these in detail will allow target-
ing of selective TGFβ responses, thereby limiting potential
consequences of inhibiting the TGFβ pathway in its
entirety. Of course, as discussed above, SIKs themselves are
known to control other pathways, including immune sig-
nalling, and these need to be considered carefully. Taking
into consideration that the clinically approved TKIs dasa-
tinib and bosutinib, which also potently inhibit SIK iso-
forms45,46, are administered to patients safely, it is
conceivable that more speciﬁc SIK inhibitors could be
applied to target certain TGFβ-associated pathologies.
Materials and methods
Antibodies
For Western immunoblotting analysis, all primary IgG
antibodies were used at 1:1000 dilution unless otherwise
stated. Anti-Phospho-SMAD3 (S423/S425) Rabbit poly-
clonal IgG (600–401–919) was purchased from Rockland
Inc. Anti-GFP Mouse monoclonal IgG (11814460001) was
purchased from Roche. Anti-Phospho-SMAD2 (S465/
S467) Rabbit polyclonal IgG (3101), anti-SMAD2/3 Rab-
bit monoclonal IgG (8685), anti-c-Myc Rabbit mono-
clonal IgG (5605), anti-p27KIP1 Rabbit monoclonal IgG
(3688), anti-p21WAF1/CIP1 Rabbit monoclonal IgG (2947),
anti-GAPDH Rabbit monoclonal IgG (used at 1:5000
dilution) (2118) and anti-SIK2 Rabbit IgG (6919) were all
purchased from Cell Signalling Technology (CST). Anti-
PAI-1 Rabbit polyclonal IgG (ab66705), anti-CTGF Rabbit
polyclonal IgG (ab6992) and anti-CRTC3 Rabbit mono-
clonal IgG (ab91654) were purchased from Abcam. Anti-
Phospho-CRTC3 (S370) Sheep polyclonal IgG (S253D,
third bleed) and anti-SIK3 Sheep polyclonal IgG (S373D,
third bleed) were generated by MRC PPU Reagents and
Services. Species-speciﬁc horseradish peroxidase (HRP)-
conjugated secondary antibodies were used at 1:5000
dilution. Rabbit anti-Sheep polyclonal IgG (H+ L) Sec-
ondary Antibody, HRP (31480) and Goat anti-Mouse
polyclonal IgG (H+ L) Secondary Antibody, HRP (31430)
were purchased from Thermo Fisher Scientiﬁc. Goat anti-
Rabbit polyclonal IgG (H+ L), HRP-conjugated Second-
ary Antibody (7074), was purchased from CST.
Cytokines and pharmacological inhibitors
Puriﬁed recombinant human TGFβ1 was purchased
from either R&D Systems or PeproTech, and recon-
stituted in sterile 4 mM HCl containing 1mgmL−1
bovine serum albumin (BSA). Prior to stimulation with
TGFβ1, cells were cultured in serum-free culture media
for ~16 h at 37 °C in order to reduce autocrine signalling.
Pharmacological inhibitors were reconstituted at 10 mM
in dimethyl sulfoxide (DMSO), and used at the con-
centrations and durations indicated in the respective
ﬁgure/ﬁgure legend. For all inhibitor experiments, control
cells were incubated with an equivalent volume of DMSO.
Generation of SIK KI mice
SIK2T175A/SIK3T163A homozygous kinase dead knock-in
(KI) mice were bred from SIK2tm1.1Arte and SIK3tm1.1Arte
mice maintained on a C57BL/6NJ genetic background
as described previously39. Primary mouse embryonic
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ﬁbroblasts (MEFs) were generated from SIK2T175A/
SIK3T163A or SIK3WT embryos at E11.5–13.5 as detailed
previously62. Primary and SV-40-immortalised MEFs
were cultured in DMEM supplemented with 20% (v/v)
FBS, 2 mM L-glutamine, 100 units mL−1 penicillin,
100 µg mL−1 streptomycin, 1× Minimum Essential
Medium (MEM) Non-Essential Amino Acids (NEAA)
and 1 mM sodium pyruvate. Mice were maintained in
individually ventilated cages, and provided with free
access to food and water under speciﬁc pathogen-free
conditions consistent with E.U. and U.K. regulations. All
animal breeding and studies were conducted following
approval by the University of Dundee Ethical Review
Committee, and performed under a U.K. Home Ofﬁce
Project Licence granted under the Animals (Scientiﬁc
Procedures) Act 1986.
Mammalian cell culture
A-172 human glioblastoma, U2OS human osteo-
sarcoma, HaCaT human immortalised keratinocyte, HEK-
293 human embryonic kidney and HeLa human cervical
adenocarcinoma cells were obtained from the MRC PPU
Tissue Culture facility, and cultured in Dulbecco’s Mod-
iﬁed Eagle’s Medium (DMEM) supplemented with 10%
(v/v) foetal bovine serum (FBS), 2 mM L-glutamine,
100 units mL−1 penicillin and 100 µgmL−1 streptomycin
(hereafter referred to as D10F media). NMuMG murine
mammary epithelial cells were cultured in D10F media
supplemented with 10 µgmL−1 insulin (from bovine
pancreas). All cell lines were maintained at 37 °C in a
humidiﬁed atmosphere with 5% (v/v) CO2 levels, and
routinely tested for mycoplasma contamination. Seeding
cell densities for each cell line was optimised to ensure
that stimulation of cells with ligands and small-molecule
inhibitors, as well as cell lysis, was performed in sub-
conﬂuent cultures.
Generation of SMAD3–/– knockout cells using CRISPR–Cas9
To generate SMAD3–/– knockout cells by CRISPR–Cas9
genome editing, HaCaT cells were transfected with the
plasmid pSpCas9(BB)-2A-GFP (PX458)63 containing both
the Cas9 endonuclease and a guide RNA (gRNA) pair
targeting exon 6 of the endogenous SMAD3 gene. For
the acquisition of single-cell knockout clones, single cells
were isolated by ﬂuorescence-activated cell sorting
(FACS) and plated in individual wells of 96-well cell
culture plates. Viable cell clones were expanded,
and successful knockouts were conﬁrmed by both
Western immunoblotting and genomic DNA sequen-
cing. Sequence of gRNA oligonucleotides: SMAD3 for-
ward gRNA 5′-CACCGGAATGTCTCCCCGACGCG
C-3′; SMAD3 reverse gRNA 5′-AAACGCGCGTCGG
GGAGACATTCC-3′.
Mammalian cell lysis
Cells were washed twice with cold 1× DPBS and incu-
bated with lysis buffer (50 mM Tris/HCl, pH 7.5, 270mM
sucrose, 150mM sodium chloride, 1 mM EDTA, pH 8.0,
1 mM EGTA, pH 8.0, 1 mM sodium orthovanadate,
10 mM sodium β-glycerophosphate, 50 mM sodium
ﬂuoride, 5 mM sodium pyrophosphate and 1% (v/v)
Nonidet P-40 (NP-40)) supplemented with Complete,
EDTA-free Protease Inhibitors (Roche) (one tablet per
25mL) for ~5min on ice. Cell lysates were transferred to
1.5-mL microcentrifuge tubes and centrifuged at 16,000 ×
g for 10 min at 4 °C, and either processed immediately or
cryopreserved in liquid nitrogen prior to storage at −80 °
C. The protein concentrations of the cell lysate samples
were determined using Pierce Coomassie (Bradford)
Protein Assay Kit (Thermo Fisher Scientiﬁc). Cell lysate
samples were subsequently diluted using 4× NuPAGE
LDS (lithium dodecyl sulfate) sample buffer (Invitrogen)
supplemented with 8% (v/v) 2-Mercaptoethanol (2-ME)
(Sigma-Aldrich) and the sample concentrations equalised.
SDS-PAGE and western blotting
Cleared cell lysates (10–20 μg of protein) or immuno-
precipitates were denatured by boiling for 5 min at 95 °C
and resolved by SDS-PAGE. The resolved proteins were
electrophoretically transferred onto Amersham Protran
0.45-μm nitrocellulose membranes (GE Healthcare Life
Sciences). Membranes were blocked using 5% (w/v) non-
fat milk in Tris-buffered saline (TBS) (50mM Tris-HCl,
pH 7.5, 150 mM NaCl) containing 0.1% (v/v) TWEEN-20
(hereafter called TBST) for 1 h at RT on a bench-top
platform rocker. The membranes were subsequently
incubated with the appropriate primary antibodies (as
detailed above) diluted in 5% (w/v) milk-TBST overnight
(~16 h) at 4 °C with continuous agitation. Following this,
membranes were washed three times for 5 min using
TBST prior to incubation with the relevant species-
speciﬁc horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies, also diluted in 5% (w/v) milk-TBST for
1 h at RT on a bench-top platform rocker. The mem-
branes were subsequently washed three times for 5 min
using TBST prior to enhanced chemiluminescence
detection, and exposed onto Medical X-Ray Film (Konica
Minolta) or Amersham Hyperﬁlm ECL (GE Healthcare
Life Sciences) under safelight conditions. The ﬁlms were
developed using an SRX-101A automated medical ﬁlm
processor (Konica Minolta).
Luciferase transcriptional reporter assay
U2OS 2G transcriptional reporter cells were seeded in
six-well cell culture plates, and incubated with the
required small-molecule inhibitors/cytokines at the
indicated concentrations and duration. Cells were
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subsequently washed twice with 1× DPBS, and lysed using
1× Cell Culture Lysis Reagent (CCLR, Promega). Cell
culture plates were incubated for ~5min on a bench-top
platform rocker to ensure efﬁcient cell lysis. Cell lysates
were transferred to 1.5-mL microcentrifuge tubes and
kept on ice. Lysate samples were vortexed for ~10 s,
centrifuged at 12,000 × g for 2 min at 4 °C and 200 µL of
supernatant was transferred to new 1.5-mL micro-
centrifuge tubes. Lysate samples were subsequently
transferred to 96-well white ﬂat-bottom cell culture
microplates. An equivalent volume of 2× Luciferase Assay
Buffer (50 mM Tris/Phosphate, pH 7.8, 16 mM MgCl2,
2 mM dithiothreitol (DTT), 1 mM adenosine triphosphate
(ATP), 30% (v/v) glycerol, 1% (w/v) bovine serum albumin
(BSA), 250 µM D-luciferin and 8 µM sodium pyropho-
sphate) was subsequently added to each well, and the
microplate incubated for ~1min on a bench-top vibrating
platform. Luminescence values were obtained using an
EnVision 2104 Multimode Microplate Reader (Perki-
nElmer). The protein concentrations of each lysate sample
were determined using Pierce Coomassie (Bradford)
Protein Assay Kit (Thermo Fisher Scientiﬁc) and used to
normalise luminescence values.
Cellular fractionation
Extraction of separate cytoplasmic and nuclear protein
fractions from cultured U2OS cells was performed using
NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Thermo Fisher Scientiﬁc) according to the manu-
facturer’s protocol. The supplied lysis buffers (CER I and
NER) were supplemented with 1× Complete, EDTA-free
Protease Inhibitors (Roche) immediately prior to use.
Subcellular fractions were reduced using NuPAGE 4×
LDS sample buffer containing 8% (v/v) 2-mercaptoetha-
nol, and incubated at 95 °C for 5 min prior to SDS-PAGE.
Fractions were resolved by SDS-PAGE and analysed via
Western immunoblotting.
Quantitative reverse transcription polymerase chain
reaction
For all reverse transcription polymerase chain reaction
(RT-qPCR) experiments, cells were seeded in six-well cell
culture plates and incubated with the required TGFβ1/
inhibitor combinations for the durations indicated in the
respective ﬁgure legends. Total RNA was isolated from
the cells using the RNeasy Micro Kit (Qiagen) according
to the manufacturer’s protocol. Complementary DNA
(cDNA) was synthesised from 0.5 to 1.0 µg of isolated
RNA using iScript cDNA Synthesis Kit (Bio-Rad)
according to the manufacturer’s protocol. All RT-qPCR
reactions were conducted in triplicate, and included 50%
(v/v) SsoFast EvaGreen Supermix (Bio-Rad), 0.5 µM for-
ward primer, 0.5 µM reverse primer and the required
volume of cDNA. RT-qPCR experiments were performed
using CFX96 or CFX384 Real-Time PCR Detection Sys-
tems (Bio-Rad). The Ct (cycle threshold) values for each
gene of interest were normalised to the arithmetic mean
Ct value of the reference gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) or 18 S ribosomal
RNA (rRNA) using Microsoft Excel software. The 2–ΔΔCt
relative quantiﬁcation method was then used to analyse
the relative changes in gene expression between control
and treatment conditions64. GraphPad Prism software
(version 8.0) was used to generate graphs and perform
statistical analysis.
Immunoﬂuorescence microscopy
U2OS GFP-SMAD2 cells were plated onto glass cov-
erslips and treated as described in the respective ﬁgure
legends. Cells were ﬁxed in 4% (v/v) paraformaldehyde
(PFA) immediately after aspirating culture media for
15min at RT before washing twice in 1× PBS. Permea-
bilisation was performed using 0.2% Triton X (Sigma) in
PBS for 10min at RT before washing twice more in 1×
PBS and blocking for 1 h at RT with 5% (w/v) BSA in PBS.
Primary antibody (anti-GFP polyclonal IgG, 1:1000 dilu-
tion) in 0.5% BSA/0.2% TWEEN-20 (Sigma)/PBS was
added to coverslips for 1 h at 37 °C before washing three
times in 0.5% BSA/0.2% TWEEN-20/PBS (10 min per
wash). Cells were incubated with the secondary Alexa-
Fluor-conjugated antibody (anti-Rabbit, 488 nm, 1:500
dilution) for 1 h at RT, before washing with 0.5% BSA/
0.2% TWEEN-20/PBS three times (20 min per wash).
During the second wash, 4′,6-Diamidino-2-Phenylindole
Dihydrochloride (DAPI, Sigma) was added at a ﬁnal
concentration of 1 µg mL−1 and removed in the ﬁnal
wash. Coverslips were rinsed in deionised H2O and
mounted onto glass microscopy slides using VECTA-
SHIELD (Vector Laboratories). Coverslips were sealed
and left to dry overnight at 4 °C. Cells were imaged using
the DeltaVision Imaging System (20× or 60× objective,
GE Healthcare), and processed using softWoRx (GE
Healthcare) and OMERO65.
Annexin V staining assay
NMuMG cells were incubated with the required cyto-
kine/inhibitor combinations. Following this, both adher-
ent and non-adherent (i.e. apoptotic) cells were collected
into 50-mL conical centrifuge tubes, pelleted by cen-
trifugation (300 × g, 2 min) and washed once using cold
1× DPBS. Cells were subsequently centrifuged (300 × g,
2 min); the cell pellets were resuspended in Annexin
Binding Buffer, ABB (10 mM HEPES, 140mM NaCl and
2.5 mM CaCl2, pH 7.4), and transferred to 1.5-mL
microcentrifuge tubes. The required cell suspension
samples were then incubated with Annexin V, Alexa-
Fluor 488 conjugate (Invitrogen, A13201) for 15min at
RT and protected from light. The appropriate samples
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were subsequently incubated with 5 µg mL−1 DAPI (4′,6-
diamidino-2-phenylindole) (Invitrogen). Samples were
immediately analysed using a BD LSRFortessa Cell Ana-
lyser (BD Biosciences) and BD FACSDiva acquisition
software (BD Biosciences). Annexin V Alexa-Fluor 488
ﬂuorescence was detected by excitation at 488 nm and
emission at 530 ± 30 nm, and DAPI ﬂuorescence was
detected by excitation at 355 nm and emission at 450 ±
50 nm. Single cells were identiﬁed on the basis of forward
light scatter (FSC) and side light scatter (SSC), and sub-
sequently evaluated for Annexin V Alexa-Fluor 488 and
DAPI ﬂuorescence. Data analysis was performed using
FlowJo Single Cell Analysis Software (BD Biosciences).
Cellular proliferation
HaCaT cells were assayed for proliferation using an
IncuCyte ZOOM Live-Cell Analysis System (Sartorius).
Cells were plated in 96-well cell culture plates (1 × 103
cells per well, 6 wells per condition, plates in triplicate)
and incubated with the required small-molecule inhibitor
in the presence or absence of recombinant human TGFβ1
(5 ng mL−1). Cells were imaged every 2 h over a period of
170 h, and the percent conﬂuence determined using
IncuCyte ZOOM Analysis Software (Sartorius).
Crystal violet cellular viability assay
NMuMG cells were seeded in 96-well cell culture plates
and incubated for 24 h at 37 °C to enable adherence of cells
to culture plates. The inclusion of wells containing culture
medium without cells were used as negative control wells.
Following the initial 24 h incubation, culture media was
aspirated and replaced with reduced serum (1% v/v FBS)
DMEM supplemented with 10 µgmL−1 bovine insulin
(Sigma-Aldrich) containing the required inhibitors or
equivalent volume of DMSO, with or without recombinant
human TGFβ1 (5 ngmL
−1), and incubated for a further
24 h. Cells were subsequently ﬁxed using 10% (v/v)
methanol/10% (v/v) acetic acid for 5min at RT, and washed
with 1× PBS. Fixed cells were stained using 0.5% (w/v)
crystal violet staining solution (0.5 g of crystal violet powder
(Sigma-Aldrich), 80mL of distilled H2O and 20mL of
methanol) for 20min at RT on a bench-top platform
rocker. Plates were subsequently washed carefully using tap
water, inverted on ﬁlter paper to remove residual liquid and
allowed to air-dry overnight. Following this, methanol was
added to each well and incubated for 20min at RT on a
bench-top platform rocker. The absorbance value of each
well was measured at 570 nm (OD570) using a 96-well
microplate spectrophotometer. The mean OD570 value of
negative control wells (i.e. wells not containing cells) was
subtracted from the values obtained from each well on the
culture plate, and the percentage of viable cells for each
condition determined relative to the mean average OD570
value of non-stimulated DMSO control-treated cells.
In vitro protein kinase assay
In all, 21-µL reaction solutions were prepared contain-
ing 200 ng of protein kinase and 2 µg of substrate protein
in 1× kinase assay buffer (50 mM Tris-HCl, pH 7.5,
0.1 mM EGTA, 10 mM magnesium acetate, 0.1% (v/v) 2-
mercaptoethanol and 0.1 mM [γ32P]-ATP). Reactions
were conducted at 30 °C for 30min at 1050 rpm and
terminated via the addition of 7 µL of NuPAGE 4× LDS
sample buffer containing 8% (v/v) 2-mercaptoethanol. For
in vitro kinase assays involving the use of small-molecule
inhibitors, reaction solutions containing all the required
components were incubated at 30 °C for 10min at
1050 rpm prior to the addition of 0.1 mM [γ32 P]-ATP.
Reactions were then performed as detailed previously.
Samples were incubated at 95 °C for 5 min, and subse-
quently centrifuged at 5.0 × 103 × g for 1 min. Samples
were loaded onto NuPAGE 4–12% Bis-Tris precast
polyacrylamide gels and resolved via SDS-PAGE. Poly-
acrylamide gels were subsequently stained with Instant-
Blue Coomassie Protein Stain (Expedeon) to visualise the
resolved recombinant proteins, and imaged using the
ChemiDoc Imaging System (Bio-Rad). 32P radioactivity
was analysed via autoradiography using Amersham
Hyperﬁlm (GE Healthcare Life Sciences).
Statistical analysis
All experiments have a minimum of three biological
replicates, unless otherwise stated in the respective ﬁgure
legend. In addition, all luciferase, RT-qPCR, cellular
proliferation, annexin V staining and crystal violet stain-
ing experiments have at least three technical repeats for
each biological replicate. The data are presented as the
arithmetic mean, with error bars denoting the standard
error of the mean (SEM). The statistical signiﬁcance of
differences between experimental conditions was assessed
by using either Student’s t test or analysis of variance
(ANOVA) with Bonferroni correction using GraphPad
Prism (version 8.0) analysis software. Differences in the
mean of experimental conditions were considered sig-
niﬁcant if the probability value (p-value) was <0.05. All
immunoblotting ﬁgures are representative.
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